- Company : Wuhan Sun-shine Bio-technology Corporation Limited
- Region : Hubei , China
- Category : Chemicals > Pharmaceutical Chemicals
- Specification : Chemical Information Product Name Pacritinib(SB1518) Iupac Chemical Name (16E)-11-[2-(1-Pyrrolidinyl)ethoxy]-14,19-dioxa-5,7,26-triazatetracyclo[19.3.1.12,6.18,12]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene Synonyms SB1518;SB 1518;SB-1518;Pacritinib;ONX 0803, BAX 2201 Molecular Formula C28H32N4O3 Molecular Weight 472.579 Smile C1(C2=NC(NC3=CC=C(OCCN4CCCC4)C(COC/C=C/COC5)=C3)=NC=C2)=CC5=CC=C1 InChiKey HWXVIOGONBBTBY-ONEGZZNKSA-N InChi InChI=1S/C28H32N4O3/c1-2-13-32(
- Contact Person : Winne He|||
- Telephone :
- Mobile phone :
- Instant Messenger : whatsapp/wechat/skype:+86 13545198479
- Update : Apr/16/2019
Product Details
Pacritinib (puh-CRIT-i-nib) is an oral tyrosine kinase inhibitor (TKI) with activity against two important activating mutations: Janus Associated Kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3). The JAK family of enzymes is a central component in signal transduction pathways, which are critical to normal blood cell growth and development as well as inflammatory cytokine expression and immune responses. Activating mutations of JAK2 are implicated in certain blood-related cancers, including myeloproliferative neoplasms (MPNs), leukemia and certain solid tumors. FLT3 is a gene commonly found mutated in patients with acute myeloid leukemia (AML). Pacritinib has demonstrated encouraging results in Phase 1 and 2 studies for patients with myelofibrosis and may offer an advantage over other JAK inhibitors through effective treatment of symptoms while having less treatment-emergent thrombocytopenia and anemia than has been seen in currently approved and in-development JAK inhibitors.
